Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Breast Neoplasms 970Neoplasms 767Carcinoma, Non-Small-Cell Lung 750Prostatic Neoplasms 577Colorectal Neoplasms 503Lung Neoplasms 447Neoplasm Metastasis 408Multiple Myeloma 376Leukemia, Myeloid, Acute 358Ovarian Neoplasms 311Pancreatic Neoplasms 306Melanoma 275Squamous Cell Carcinoma of Head and Neck 259Recurrence 248Carcinoma, Hepatocellular 233Glioblastoma 225Brain Neoplasms 221Head and Neck Neoplasms 202Triple Negative Breast Neoplasms 200Carcinoma, Renal Cell 200Lymphoma 192Precursor Cell Lymphoblastic Leukemia-Lymphoma 191Stomach Neoplasms 189Endometrial Neoplasms 179Lymphoma, Non-Hodgkin 175Sarcoma 169Glioma 168Uterine Cervical Neoplasms 167Lymphoma, Large B-Cell, Diffuse 160Hematologic Neoplasms 159

Interventions

lutetium Lu 177 dotatate 1X-Rays 1Specimen Handling 1Photons 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Lung Neuroendocrine Tumor × 90 days × Clear all
NCT04665739 2026-05-13

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
70 enrolled
EndocrineNET

Advanced Lung Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡